Clinical and Technical Review - Tecomedical
Clinical and Technical Review - Tecomedical
Clinical and Technical Review - Tecomedical
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
8<br />
Bone marker <strong>and</strong> characteristics<br />
Biomarker Method Main<br />
Sample<br />
Type<br />
Formation<br />
BAP<br />
Osteocalcin<br />
Intact<br />
Osteocalcin<br />
N-mid<br />
PINP<br />
PICP = CICP<br />
Resorption<br />
ICTP =<br />
CTX-MMP<br />
Others<br />
ELISA<br />
IRMA/<br />
ELISA<br />
ELISA<br />
RIA<br />
ELISA<br />
Serum<br />
Serum<br />
Serum<br />
Serum<br />
Serum<br />
A(a) B C D E F G H<br />
Pre- &<br />
postmenopause<br />
+<br />
+<br />
+<br />
+<br />
NA<br />
Analytical<br />
variation<br />
+<br />
+<br />
+<br />
+<br />
+<br />
Treatment<br />
response<br />
Short<br />
time<br />
change<br />
Within<br />
person<br />
variation<br />
Daily<br />
variation<br />
Food<br />
intake<br />
TRAP 5b ELISA Serum ± + ± ± NA + + ±<br />
DPD ELISA Urine + + + + + - + +<br />
NTx ELISA<br />
CTx ELISA<br />
+<br />
+<br />
+<br />
+<br />
+<br />
Sample<br />
stability<br />
Scores sind: + (yes), - (no), ± (fair/indeterminate), NA (not available)<br />
(a) Letters correspond to following, the marker:<br />
H. preferably demonstrates high stability in the biological<br />
A. shows a difference in the rate of bone turnover pre-<strong>and</strong><br />
specimen<br />
post-menopause<br />
(b) In contrast to OPG, sRANKL showed no response to<br />
B. demonstrates minimal analytical variation<br />
bisphosphonate treatment of osteoporotic postmeno-<br />
C. significantly changes in response to treatment<br />
pausal women. However, PTH treatment of glucocorticoid<br />
D. detect changes in short time interval (months)<br />
induced osteoporotic women resulted in a fast (1 month)<br />
E. demonstrates minimal within person (biological) variation <strong>and</strong> sustained increase of sRANKL levels.<br />
F. preferably demonstrates little variation over the day<br />
(c) Cathepsin K is elevated in patients with established<br />
G. no influence by food intake<br />
rheumatoid arthritis.<br />
+<br />
+<br />
+<br />
+<br />
+<br />
+<br />
±<br />
±<br />
±<br />
+<br />
+<br />
+<br />
+<br />
+<br />
±<br />
+<br />
+<br />
+<br />
+<br />
+<br />
+<br />
-<br />
+<br />
+<br />
+<br />
5 days<br />
2–8 °C<br />
4hours<br />
2–8 °C<br />
5 days<br />
2–8 °C<br />
5 days<br />
2–8 °C<br />
5 days<br />
2–8 °C<br />
2 days<br />
2–8 °C<br />
7 days<br />
2–8 °C<br />
Serum + + + + + - ± ± 1day<br />
2–8 °C<br />
Urine + + + + ± - ± +<br />
3 days<br />
2–8 °C<br />
Serum + + + + + - - + 1day<br />
2–8 °C<br />
Urine + + + + ± - - +<br />
ELISA Serum - + - - NA ± + +<br />
7 days<br />
2–8 °C<br />
5 days<br />
2–8 °C<br />
sRANKL ELISA Plasma NA + ± (b) - NA NA + ± 1day<br />
2–8 °C<br />
Osteoprotegerin<br />
(OPG)<br />
ELISA Plasma NA + + - NA NA + ± 1day<br />
2–8 °C<br />
Cathepsine K ELISA Serum NA (c) + NA NA NA NA + ±<br />
2 days<br />
2–8 °C